Edition:
United States

VistaGen Therapeutics Inc (VTGN.OQ)

VTGN.OQ on NASDAQ Stock Exchange Capital Market

1.17USD
13 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.17
Open
--
Day's High
--
Day's Low
--
Volume
100
Avg. Vol
164,749
52-wk High
$3.91
52-wk Low
$0.69

Latest Key Developments (Source: Significant Developments)

Sabby Management LLC Reports A 9.15 Pct Passive Stake In Vistagen Therapeutics
Thursday, 14 Dec 2017 10:19am EST 

Dec 14 (Reuters) - Vistagen Therapeutics Inc ::SABBY MANAGEMENT LLC REPORTS A 9.15 PCT PASSIVE STAKE IN VISTAGEN THERAPEUTICS INC <<>> AS OF DEC 11 - SEC FILING.  Full Article

Vistagen Therapeutics posts Q2 loss of $0.53 per share
Thursday, 9 Nov 2017 04:30pm EST 

Nov 9 (Reuters) - Vistagen Therapeutics Inc :Vistagen therapeutics reports second fiscal quarter 2018 financial results and provides business update.Qtrly ‍basic and diluted net loss attributable to common stockholders per common share​ of $0.53.  Full Article

VistaGen Therapeutics files for offering of up to $23 mln of common stock
Wednesday, 18 Oct 2017 05:49pm EDT 

Oct 19 (Reuters) - VistaGen Therapeutics Inc :VistaGen Therapeutics Inc files for offering of up to $23 million of common stock – SEC filing‍​.  Full Article

Vistagen to buy up to 1.9 mln shares of common stock at $1.75 per share
Thursday, 31 Aug 2017 09:10am EDT 

Aug 31 (Reuters) - Vistagen Therapeutics Inc :Vistagen announces pricing of underwritten offering of common stock and warrants to purchase common stock.Vistagen Therapeutics Inc - ‍pricing of an underwritten public offering of 1.4 mlnshares of its common stock and warrants​.Vistagen Therapeutics Inc - to purchase up to 1.9 million shares of common stock at an offering price of $1.75 per share and related warrants​.Vistagen Therapeutics Inc - ‍gross proceeds of offering are expected to be approximately $2.4 million​.  Full Article

Vistagen Therapeutics' largest stockholder signs 6-month lock-up agreement
Monday, 1 May 2017 08:00am EDT 

May 1 (Reuters) - Vistagen Therapeutics Inc :Vistagen Therapeutics' largest stockholder signs 6-month lock-up agreement.Vistagen Therapeutics - under agreement, stockholder and its affiliates agreed to not enter into any transaction involving co's securities during term of agreement.Vistagen Therapeutics - term of agreement runs through late-Oct. 2017 and covers about 36 pct of co's issued, outstanding equity securities on an as converted basis.  Full Article

Vistagen Therapeutics says European Patent Office has issued a notice of intention to grant company's European patent application for AV-101
Wednesday, 29 Mar 2017 09:00am EDT 

Vistagen Therapeutics Inc :Vistagen Therapeutics says European Patent Office (EPO) has issued a notice of intention to grant company's European patent application for AV-101.  Full Article

Vistagen Therapeutics provides business outlook
Thursday, 22 Sep 2016 08:05am EDT 

Vistagen Therapeutics Inc : Vistagen Therapeutics provides business outlook and sets corporate milestones . Says Vistagen expects to report topline data from its NIMH-sponsored Phase 2a study in Q2 of 2017 . Expects to receive FDA fast track designation for AV-101 as adjunctive treatment for MDD during first half of 2017. .Company anticipates topline results for AV-101 from Phase 2b study to be reported in Q3 of 2018.  Full Article

Sphera Funds Management reports 7.6 pct passive stake in Vistagen Therapeutics as of May 11, 2016
Wednesday, 22 Jun 2016 09:46am EDT 

Vistagen Therapeutics Inc : Sphera Funds Management Ltd reports 7.6 percent passive stake in Vistagen Therapeutics Inc as of May 11, 2016 - Sec filing Source - http://1.usa.gov/28PKYsC (Bengaluru Newsroom; +1 646 223 8780).  Full Article

Vistagen Therapeutics appoints Mark Smith as chief medical officer
Monday, 20 Jun 2016 08:01am EDT 

Vistagen Therapeutics Inc : Appoints Mark A. Smith, as chief medical officer . Expects to report topline data from phase 2A clinical study in Q2 of 2017 and is preparing to advance AV-101 into a phase 2B .Vistagen Therapeutics appoints pharmaceutical CNS drug development executive Mark A. Smith M.D., PH.D. as chief medical officer.  Full Article

Empery Asset Management reports 9.87 pct passive stake in Vistagen Therapeutics
Thursday, 19 May 2016 04:16pm EDT 

Vistagen Therapeutics Inc :Empery Asset Management Lp reports 9.87 pct passive stake in Vistagen Therapeutics Inc, as of May 11, 2016 - SEC filing.  Full Article

BRIEF-Sabby Management LLC Reports A 9.15 Pct Passive Stake In Vistagen Therapeutics

* SABBY MANAGEMENT LLC REPORTS A 9.15 PCT PASSIVE STAKE IN VISTAGEN THERAPEUTICS INC AS OF DEC 11 - SEC FILING Source text: (http://bit.ly/2ksLZuU) Further company coverage: